Preferred Label : telaprevir;
MeSH note : a hepatitis C virus serine protease inhibitor; structure in first source;
CISMeF synonym : VX 950; incivek;
MeSH hyponym : VX950 cpd; VX-950;
Is substance : O;
UNII : 655M5O3W0U;
InChIKey : BBAWEDCPNXPBQM-GDEBMMAJSA-N;
Origin ID : C486464;
UMLS CUI : C1876229;
ATC code(s)
- CISMeF manual mappings
- Exact mapping(s) to DCI
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
http://www.has-sante.fr/portail/jcms/c_1751171/fr/incivo
http://www.has-sante.fr/portail/jcms/c_1189487/incivo
2014
false
France
French
guidelines for drug use
oligopeptides
oligopeptides
telaprevir
telaprevir
telaprevir
administration, oral
insurance, health, reimbursement
protease inhibitors
protease inhibitors
drug therapy, combination
hepatitis C, chronic
NS3 protein, hepatitis C virus
viral nonstructural proteins
treatment outcome
adult
controlled clinical trials as topic
evaluation of the transparency committee
---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/23481a-fra.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/23483a-fra.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/23481a-eng.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/23483a-eng.php
2013
false
Canada
English
French
drug hypersensitivity syndrome
telaprevir
telaprevir
drug therapy, combination
hepatitis C, chronic
serine proteinase inhibitors
canada
pharmacovigilance note
patient education handout
eosinophilia
drug hypersensitivity
stevens-johnson syndrome
syndrome
oligopeptides
Drug reaction with eosinophilia and systemic symptoms
---
https://www.ema.europa.eu/medicines/human/EPAR/Incivo
2012
false
United Kingdom
English
French
summary of product characteristics
package leaflet
drug information
syndication feed
telaprevir
viral nonstructural proteins
NS3 protein, hepatitis C virus
telaprevir
telaprevir
drug approval
treatment outcome
administration, oral
hepatitis C, chronic
drug therapy, combination
antiviral agents
antiviral agents
oligopeptides
oligopeptides
adult
protease inhibitors
protease inhibitors
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
Summary Basis of Decision (SBD) for Incivek
Telaprevir, 375 mg, Tablet, Oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00070
2012
false
Canada
English
French
drug information
Product containing precisely telaprevir 375 milligram/1 each conventional release
oral tablet (clinical drug)
telaprevir
telaprevir
telaprevir
administration, oral
antiviral agents
antiviral agents
protease inhibitors
drug therapy, combination
hepatitis C, chronic
NS3 protein, hepatitis C virus
risk assessment
treatment outcome
drug approval
canada
clinical trials, phase ii as topic
clinical trials, phase iii as topic
viral nonstructural proteins
oligopeptides
oligopeptides
---
http://www.has-sante.fr/portail/jcms/c_1241054/incivo-telaprevir-inhibiteur-de-protease
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-04/incivo_14122011_synthese_ct11500.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-01/incivo_14_12_2011_avis_ct11500.pdf
2011
false
France
French
drug hypersensitivity syndrome
telaprevir
telaprevir
telaprevir
administration, oral
hepatitis C, chronic
drug therapy, combination
protease inhibitors
protease inhibitors
insurance, health, reimbursement
NS3 protein, hepatitis C virus
treatment outcome
clinical trials, phase iii as topic
adult
NS4A cofactor peptide, hepatitis C virus
viral nonstructural proteins
carrier proteins
oligopeptides
oligopeptides
guidelines for drug use
evaluation of the transparency committee
---
